COST OF PERIPHERAL FACIAL PALSY TREATMENT WITH BOTULINUM TOXIN TYPE A.

Author(s):  
David Hernandez Herrero ◽  
Eishe Abdel Muti García ◽  
Jose López Araujo ◽  
Ejessie Alfonso Barrera ◽  
Susana Moraleda Pérez
2006 ◽  
Vol 99 (10) ◽  
pp. 829-834
Author(s):  
Hiroo Inamura ◽  
Hidehiro Koshu ◽  
Kazuhiro Kawaguchi ◽  
Yasuhiro Abe ◽  
Masaru Aoyagi

2014 ◽  
Vol 124 (11) ◽  
pp. 2513-2517 ◽  
Author(s):  
Anna Dall'Angelo ◽  
Silvia Mandrini ◽  
Vittorio Sala ◽  
Chiara Pavese ◽  
Ettore Carlisi ◽  
...  

Toxins ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 159
Author(s):  
Carla de Sanctis Pecora ◽  
Danielle Shitara

Unilateral peripheral facial nerve palsy jeopardizes quality of life, rendering psychological consequences such as low self-esteem, social isolation, anxiety, and depression. Among therapeutical approaches, use of Botulinum toxin type A (BoNT-A) on the nonparalyzed side has shown promising results and improvement of quality of life. Nevertheless, the correct technique is paramount, since over-injection of the muscles can result in lack of function, leading to a “paralyzed” appearance, and even worse, functional incompetence, which may cause greater distress to patients. Therefore, the objective of this article is to provide a practical guideline for botulinum toxin use in facial palsy. To this aim, adequate patient assessment, BoNT-A choice, injection plan and dosage, and injection techniques are covered.


2005 ◽  
Vol 18 (1) ◽  
pp. 29
Author(s):  
Dong Eon Moon ◽  
Young Eun Moon ◽  
Shi Hyeon Kim ◽  
Eun Sung Kim

Sign in / Sign up

Export Citation Format

Share Document